Anti-B7H3 chimeric antigen receptor and application thereof

A technology of chimeric antigen receptor and antigen, applied in the field of biomedicine

Active Publication Date: 2021-03-19
GUANGZHOU BIO GENE TECH CO LTD
View PDF7 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-B7H3 chimeric antigen receptor and application thereof
  • Anti-B7H3 chimeric antigen receptor and application thereof
  • Anti-B7H3 chimeric antigen receptor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0131] Example 1 Preparation of CAR-T cells

[0132] In this example, anti-B7H3 antibodies H26B6, H2B8, 26B6, 2B8, 23H1, 6F7, Enoblituzumab (Eno) and huM30 were selected as the antigen-binding domains to construct CAR molecules. Among them, 26B6 and its humanized H26B6, 2B8 and its humanized H2B8, 23H1, and 6F7 have significant binding ability to B7H3, not only can bind to free B7H3 protein, but also can bind to cell surface B7H3 protein; huM30 is a humanized B7H3 antibody (CN103687945B) from Daiichi Sankyo (Japan). ), is conducting a phase I clinical trial for the treatment of B7H3-positive solid tumors (NCT02192567); Enoblituzumab (MGA271) is a new monoclonal antibody that has been optimized by immune molecules, targeting the B7H3 target, by MacroGenics using exclusive Fc optimization technology Developed, with unique antibody advantages and therapeutic potential, no such drug has been approved in the world, Enoblituzumab represents the world's leading B7H3 antibody drug.

...

Example Embodiment

[0149] Example 2 Expression efficiency of CAR by CAR-T cells

[0150] The expression rate of CAR in CAR-T cells was detected by flow cytometry.

[0151] like Figure 3A As shown, the expression rate of CAR in H26B6-CAR-T cells was 65.72%, and the expression rates of CAR in H2B8-CAR-T, L2B8-CAR-T, and L26B6-CAR-T cells were 31.73%, 38.15%, and 44.14%, respectively.

[0152] like Figure 3B As shown, the expression rate of CAR in Eno-CAR-T cells was 27.3%, and the expression rate of CAR in huM30-CAR-T cells was 45.2%.

[0153] In another experiment, as Figure 3C As shown, the expression rate of CAR in huM30-CAR-T cells was 23.09%, and the expression rate of CAR in 26B6-CAR-T cells was 7.67%;

[0154] In another experiment, as Figure 3D As shown, the expression rate of CAR in huM30-CAR-T cells was 33.12%, the expression rate of CAR in L2B8-CAR-T cells was 33.43%, and the expression rate of CAR in 2B8-CAR-T cells was 12.55%.

Example Embodiment

[0155] Example 3 Killing function of CAR-T cells

[0156] H26B6-CAR-T, H2B8-CAR-T, L2B8-CAR-T, L26B6-CAR-T were combined with human liver cancer cell HepG2, human pancreatic cancer cell PL45, and human cervical cancer cell SiHa in a ratio of 2:1, 1:1 , 1:4 effector-target ratio was incubated for 16h, and the killing efficiency of CAR-T was detected by RTCA technology.

[0157] Figure 4A , Figure 4B , Figure 4C The results showed that the four CAR-T cells had killing effects on the three tumor cells under different effector-target ratios, and the larger the effector-target ratio, the stronger the killing ability; when the effector-target ratio was 2:1, H26B6-CAR-T cells The killing efficiency of T on three tumor cells was better than that of H2B8-CAR-T, L2B8-CAR-T and L26B6-CAR-T.

[0158] Different CAR-T cells (huM30-CAR-T and 2B8-CAR-T) were prepared from PBMCs of healthy donors (donor 1 and donor 2), and the target cells were 3:1, 1:1, 1 The effector-target ratio of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an anti-B7H3 chimeric antigen receptor and application thereof. The anti-B7H3 chimeric antigen receptor comprises an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain, wherein the antigen binding domain is an anti-human B7H3 antibody. The anti-B7H3 chimeric antigen receptor has a specific targeting effect on B7H3 positive tumor cells, T cells expressing the anti-B7H3 chimeric antigen receptor have a remarkable in-vitro and in-vivo killing effect, the B7H3 positive tumor cells can be effectively removed, and the anti-B7H3 chimeric antigen receptor has important significance in the field of tumor treatment.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to an anti-B7H3 chimeric antigen receptor and its application. Background technique [0002] B7H3 is a type I transmembrane protein, which belongs to the B7 immune co-stimulatory and co-inhibitory family. It has immunosuppressive function, can reduce the type I interferon (IFN) released by T cells, and reduce the cytotoxicity of NK cells. B7H3 protein has limited expression in normal tissues (such as prostate, breast, placenta, liver, colon and lymphoid organs), but abnormally high expression in most malignant tumors. The expression of B7H3 can be detected in non-small cell lung cancer cell lines and tumor tissues. In B7H3-expressing tumor tissues, the number of infiltrating lymphoid cells was significantly reduced and positively correlated with lymph node metastasis (Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer[J].Lung Cancer,2006,53(2)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N5/10C12N5/0783A61K39/00A61P35/00A61P35/02
CPCC07K16/2827C07K14/7051C12N5/0636C12N15/86A61K39/001111A61P35/00A61P35/02C07K2319/02C07K2319/03C12N2510/00C12N2740/15043A61K2039/5158
Inventor 罗敏李光超周兆王学俊
Owner GUANGZHOU BIO GENE TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap